A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects with Idiopathic Pulmonary Fibrosis (ATLAS)

Trial ID or NCT#

NCT01759511

Status

not recruiting iconNOT RECRUITING

Purpose

This study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with Idiopathic Pulmonary Fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.

View on ClinicalTrials.gov